SCHEMBL29384841

SCHEMBL29384841

CN1CCN(C2=Nc3cccnc3Sc3ccccc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 3/20 0.59
DRD2 P14416 3/20 0.56
LMNA P02545 1/20 0.56
CHRM2 P08172 1/20 0.56
HTR1A P08908 1/20 0.56
ADRA2A P08913 1/20 0.56
CHRM1 P11229 1/20 0.56
ADRA2B P18089 1/20 0.56
ADRA2C P18825 1/20 0.56
CHRM3 P20309 1/20 0.56
DRD1 P21728 1/20 0.56
SLC6A2 P23975 1/20 0.56
HTR2A P28223 1/20 0.56
HTR2C P28335 1/20 0.56
SLC6A4 P31645 1/20 0.56
ADRA1A P35348 1/20 0.56
HRH1 P35367 1/20 0.56
OPRM1 P35372 1/20 0.56
DRD3 P35462 1/20 0.56
OPRD1 P41143 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9181334 1.00 HRH4 (0.59) HRH4DRD2LMNACHRM2HTR1A
SCHEMBL11559143 0.90 DRD2 (0.59) HRH4DRD2LMNACHRM2HTR1A
SCHEMBL9178906 0.88 HRH4 (0.53) HRH4DRD2ADRA2AHTR2ADRD4
SCHEMBL9211771 0.85 DRD2 (0.72) HRH4DRD2LMNACHRM2HTR1A
SCHEMBL144624 0.84 DRD2 (0.74) HRH4DRD2LMNACHRM2HTR1A
SCHEMBL140462 0.78 HRH4 (0.65) HRH4DRD2LMNACHRM2HTR1A
SCHEMBL29407324 0.78 HRH4 (0.65) HRH4DRD2LMNACHRM2HTR1A
Fumaric Acid SCHEMBL9174545 0.78 DRD4 (0.62) HRH4DRD2LMNACHRM2HTR1A
Fumaric Acid SCHEMBL9174551 0.78 DRD4 (0.62) HRH4DRD2LMNACHRM2HTR1A
SCHEMBL8022151 0.76 DRD2 (0.80) HRH4DRD2LMNACHRM2HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119140287-A Equal floatable separation process for lepidolite containing mud 江西九岭锂业股份有限公司 2024-12-17 CN claimed
US-20240067689-A1 INTERLEUKIN-2 FUSION PROTEINS AND USES THEREOF MEDICENNA THERAPEUTICS INC (CA) 2024-02-29 US claimed
CN-114704874-B Precise control method for heating parameters of heating power station based on flexible heating system 内蒙古思铂睿特节能科技有限公司 2023-12-19 CN claimed
CN-115873668-A Formula of integrated plant compounded plant type laundry detergent for daily chemical products 贵州华波日化有限公司 2023-03-31 CN claimed
CN-114704874-A Accurate control method for heating parameters of heating station based on flexible heating system 内蒙古思铂睿特节能科技有限公司 2022-07-05 CN claimed
US-20260144857-A1 SHIGELLA MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION AND FUSION PROTEINS THEREOF THE CHILDREN'S MEDICAL CENTER CORPORATION (US) 2026-05-28 US disclosed
US-20260116940-A1 MASKED CYTOKINE POLYPEPTIDES XILIO DEV INC (US) 2026-04-30 US disclosed
CN-119140287-B Equal floatable separation process for lepidolite containing mud 江西九岭锂业股份有限公司 2025-09-19 CN disclosed
US-20250282851-A1 Monoclonal Antibody A38 Against Rift Valley Fever Virus and Use ACADEMY OF MILITARY MEDICAL SCIENCE, PLA (CN) 2025-09-11 US disclosed
US-20250207850-A1 BREWING AND COOLING A BEVERAGE COLDSNAP, CORP. 2025-06-26 US disclosed
EP-3823592-B1 COMPOSITIONS AND METHODS FOR CONTROLLED RELEASE OF TARGET AGENT UNIV HONG KONG SCIENCE & TECH (CN) 2025-06-25 EP disclosed
WO-2025118037-A1 BINDING PROTEINS AND METHODS AND USES THEREOF MACFARLANE BURNET INSTITUTE FOR MEDICAL RESEARCH AND PUBLIC HEALTH LIMITED (AU) 2025-06-12 WO disclosed
WO-2022140354-A1 ARTIFICIAL ANTIGEN-SPECIFIC IMMUNOREGULATORY T (AIRT) CELLS Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) 2022-06-30 WO disclosed
CN-114676497-A Underwater vehicle reliability verification method based on Bayes method 中国人民解放军海军工程大学 2022-06-28 CN disclosed
WO-2022132696-A1 UREA OREXIN RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2022-06-23 WO disclosed
EP-3972997-A1 NOVEL ANTI-CD25 ANTIBODIES Institut National de la Santé et de la Recherche Médicale (INSERM) (FR) 2022-03-30 EP disclosed
CN-106732749-B One-step synthesis preparation method of hydrocracking catalyst 中国海洋石油集团有限公司 2022-03-29 CN disclosed
EP-3969447-A1 CYANO CYCLOBUTYL COMPOUNDS FOR CBL-B INHIBITION AND USES THEREOF Nurix Therapeutics, Inc. (US) 2022-03-23 EP disclosed
CN-114107122-A Method for relieving gout by using probiotic fermented food slurry 兰州大学 2022-03-01 CN disclosed
WO-2022035863-A1 METHOD FOR TREATING CARDIAC CONDITIONS WITH PLACENTA-DERIVED COMPOSITIONS MUSCULOSKELETAL TRANSPLANT FOUNDATION (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260144857-A1 SHIGELLA MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION AND FUSION PROTEINS THEREOF HLA-DRB1, SPOP, STXBP1 HRH4 4616/4885DRD2 3382/4885LMNA 2338/4885
US-20260116940-A1 MASKED CYTOKINE POLYPEPTIDES TNFRSF9, IL36G, TNFSF11 HRH4 1174/4885DRD2 4320/4885LMNA 1674/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.